Pre-Approval Information Exchange Act of 2022
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Pre-Approval Information Exchange Act of 2022
This bill specifies that product information that is exchanged between drug manufacturers and certain health care entities (e.g., formulary committees) about drug products before regulatory approval is not considered to be misbranding if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.
Referred to the Subcommittee on Health.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 9297: Pre-Approval Information Exchange Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-HR-9297/
"H.R. 9297: Pre-Approval Information Exchange Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-9297/.
H.R. 9297, 117th Cong. (2026), https://openamerica.io/bill/117-HR-9297/.
[H.R. 9297: Pre-Approval Information Exchange Act of 2022](https://openamerica.io/bill/117-HR-9297/)